Fetal stem cell infusion for chronic obstructive pulmonary disease
Tests fetal stem cell infusions in adults with moderate to severe COPD.
Plain-language title generated from the registry record
Registry title: cfMSC Stem Cell Therapy Targeting COPD
Key facts
- Where
- Shenzhen, ChinaSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Source: NCT07477600, who can take part
Where in China
- Shenzhen Geno-immune Medical InstituteShenzhen, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shenzhen Geno-Immune Medical Institute
- Trial code
- NCT07477600
- Record updated
- 2 November 2026
- Original description
The primary objectives are to evaluate the safety and efficacy of infusion of fully characterized clonally derived fetal mesenchymal stem cells (cfMSCs) for the control of severe symptoms associated with moderate to severe chronic obstructive pulmonary disease.Read full original descriptionShow less
Clonal Fetal Mesenchymal Stem Cell Therapy for the Treatment of Chronic Obstructive Pulmonary Disease
The primary objectives are to evaluate the safety and efficacy of infusion of fully characterized clonally derived fetal mesenchymal stem cells (cfMSCs) for the control of severe symptoms associated with moderate to severe chronic obstructive pulmonary disease.
Inclusion: Ability to understand the study protocol and the willingness to provide written informed consent; Age 40-80 years old, male or female; Diagnosed with moderate to severe COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (GOLD Ⅱ-Ⅳ); Regular use of COPD conventional drugs for more than 3 months, and the condition is stable for more than 4 weeks; ineffective clinical treatment; Life expectancy > 6 months; At least six months smoking cessation, including non-smoking during the treatment and follow-up periods of the study.
Exclusion: Combined with other serious lung diseases: asthma, active pulmonary tuberculosis, bronchiectasis, pulmonary embolism, interstitial lung disease, pulmonary hypertension, etc; A history of lung surgery (pneumonectomy, lung volume reduction surgery, etc.) or bronchial intervention surgery within 12 months; Negative for HIV, HCV or syphilis serology; A history of malignant tumors or malignant tumors under treatment; Autoimmune diseases requiring long-term use of glucocorticoids or immunosuppressants; A history of alcohol or drug abuse, or mental diseases that cannot cooperate with the study; Poorly controlled diabetes (fasting blood glucose > 10.0 mmol/L) or severe metabolic diseases; Invasive or non-invasive mechanical ventilation history within 4 weeks, or moderate to severe acute exacerbation of COPD within 4 weeks; Pregnancy or breastfeeding; Unable or unwilling to comply with study specific schedules or procedures.